Business Context and Reporting Period
Company: Disc Medicine, Inc. (Nasdaq: IRON)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Disc Medicine is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious hematologic diseases. Its pipeline includes bitopertin (for erythropoietic porphyrias and Diamond-Blackfan Anemia), DISC-0974 (for anemia of myelofibrosis and chronic kidney disease), and DISC-3405 (for polycythemia vera). The company has no products approved for commercial sale and has not generated any revenue from product sales.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(34,085) | $(26,949) |
| Net Loss Per Share (Basic & Diluted) | $(1.02) | $(1.09) |
| Operating Expenses | $39,946 | $31,462 |
| Research & Development (R&D) | $27,763 | $23,704 |
| Selling, General & Administrative (SG&A) | $12,183 | $7,758 |
| Interest Income | $6,880 | $4,519 |
| Interest Expense | $(897) | $0 |
| Cash, Cash Equivalents & Marketable Securities | $694,662 | $489,881 |
| Long-Term Debt (Net) | $28,529 | $0 |
| Accumulated Deficit | $(332,087) | $(215,594) |
Note: Cash, cash equivalents, and marketable securities for Q1 2024 calculated from Balance Sheet data ($192,434 cash + $297,447 marketable securities).
Material Changes vs. Prior Period
- Capital Raise: In January 2025, the company completed an underwritten offering of common stock and pre-funded warrants, raising net proceeds of approximately $243.4 million. This significantly increased total liquidity to $694.7 million as of March 31, 2025.
- Debt Financing: In November 2024, the company entered into a Loan and Security Agreement with Hercules Capital, Inc., borrowing an initial $30.0 million. This resulted in interest expense of $0.9 million in Q1 2025, compared to none in Q1 2024.
- Expense Growth: Total operating expenses increased by $8.5 million (27%) year-over-year.
- R&D Expenses: Increased by $4.1 million, driven by higher development costs for DISC-0974 and bitopertin, and increased personnel-related costs.
- SG&A Expenses: Increased by $4.4 million, primarily due to higher personnel costs and a $2.1 million increase in legal and professional fees related to commercialization preparations.
- Investing Activities: Net cash used in investing activities was $272.6 million in Q1 2025, primarily due to the purchase of marketable securities ($347.3 million) following the capital raise, compared to minimal investing activity in Q1 2024.
Guidance, Outlook, and Risks
- Development Milestones:
- Bitopertin: The company initiated the APOLLO clinical trial (a randomized, double-blind, placebo-controlled trial) in 2025. Management anticipates submitting a New Drug Application (NDA) for accelerated approval in EPP and XLP in the second half of 2025.
- DISC-0974: The company expects to report initial data from the Phase 2 trial in anemia of myelofibrosis and the Phase 1b trial in non-dialysis dependent CKD in the second half of 2025.
- DISC-3405: A Phase 2 clinical trial is planned for initiation in the first half of 2025.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($694.7 million) are sufficient to fund operations and debt service obligations into 2028, excluding potential revenue from approved products.
- Internal Controls: The company identified a material weakness in internal control over financial reporting related to Information Technology General Controls (ITGCs). Remediation efforts are underway, but the weakness remains as of March 31, 2025.
- Risk Factors: Key risks include the failure of clinical trials, inability to obtain regulatory approval, reliance on third-party manufacturers, potential dilution from future capital raises, and the impact of the material weakness in internal controls.
Investor Verification Checklist
- Cash Runway: Verify the $694.7 million liquidity position and the assumption that it funds operations through 2028.
- Debt Covenants: Review the terms of the Hercules Loan Agreement, specifically the minimum cash covenant effective January 1, 2027, and the "End of Term Charge" of 6.75%.
- Regulatory Pathway: Confirm the FDA's continued acceptance of protoporphyrin IX (PPIX) reduction as a surrogate endpoint for bitopertin's accelerated approval.
- Internal Controls: Monitor the progress of remediation for the identified material weakness in ITGCs to ensure future financial reporting reliability.
- Clinical Trial Progress: Track enrollment and data readouts for the APOLLO (bitopertin), DISC-0974, and DISC-3405 trials as scheduled for the second half of 2025.